Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkae116 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Heinz-Josef Lenz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Colorectal Neoplasms, Fluorouracil. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: G1 Therapeutics, Inc.
Abstract (Originalsprache)
Background
In metastatic colorectal cancer (mCRC), improvements in survival from combining leucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) with bevacizumab have come at the risk of increased rates of high-grade toxicities. Trilaciclib is indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients receiving standard-of-care chemotherapy for extensive-stage small cell lung cancer.
Methods
Patients with untreated mCRC were randomly assigned 1:1 to trilaciclib (n = 164) or placebo (n = 162) prior to FOLFOXIRI/bevacizumab for up to 12 cycles (induction), followed by trilaciclib or placebo prior to fluorouracil/leucovorin/bevacizumab (maintenance). Co-primary endpoints were duration of severe (grade 4) neutropenia (DSN) in cycles 1-4 and occurrence of severe neutropenia (SN) during induction. Secondary endpoints included antitumor efficacy, survival, and safety.
Results
The study met its co-primary endpoints. Administering trilaciclib prior to FOLFOXIRI/bevacizumab resulted in significant reductions in DSN in cycles 1-4 vs placebo (mean, 0.1 vs 1.3 days; P < .001) and occurrence of SN during induction (1.3% vs 19.7%; adjusted relative risk [96% CI] = 0.07 [0.0 to 0.3]; P < .001). Grade 3/4 adverse events, including neutropenia, diarrhea, and leukopenia, were less frequent with trilaciclib vs placebo (64.8% vs 73.1%). Trilaciclib was associated with fewer chemotherapy dose reductions and delays and with reduced administration of supportive therapies, compared with placebo. Objective response rate (41.6% vs 57.1%; P = .009) and median progression-free survival (10.3 vs 13.1 months; P < .001) were significantly lower with trilaciclib vs placebo.
Conclusions
Administering trilaciclib prior to FOLFOXIRI/bevacizumab protected the neutrophil lineage from the effects of chemotherapy-induced myelosuppression. However, antitumor efficacy endpoints favored placebo.
Trial registration
ClinicalTrials.gov: NCT04607668.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States.
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Medicine, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, United States.
- Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét 6000, Hungary.
- Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, City Multifield Clinical Hospital, Dnipropetrovsk 49102, Ukraine.
- Department of Clinical Oncology, Szpitale Pomorskie Sp. z o.o., Gdynia 81-519, Poland.
ORCID-Profile: Heinz-Josef Lenz, Tianshu Liu, Emerson Y Chen, Zsolt Horváth, Igor Bondarenko, Iwona Danielewicz, Michele Ghidini, Pilar García-Alfonso, Robert Jones, Matti Aapro, Wayne Wang, Andrew Beelen, Joleen Hubbard
Förderung
- G1 Therapeutics, Inc
Zitieren
APA
Lenz, H. J., Liu, T., Chen, E. Y., Horváth, Z., Bondarenko, I., Danielewicz, I., Ghidini, M., García-Alfonso, P., Jones, R., Aapro, M., Zhang, Y., Wang, J., Wang, W., Adeleye, J., Beelen, A., & Hubbard, J. (2025). Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae116
Vancouver
Lenz HJ, Liu T, Chen EY, Horváth Z, Bondarenko I, Danielewicz I, et al. Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkae116
BibTeX
@article{Lenz2025,
author = {Lenz, Heinz-Josef and Liu, Tianshu and Chen, Emerson Y and Horváth, Zsolt and Bondarenko, Igor and Danielewicz, Iwona and Ghidini, Michele and García-Alfonso, Pilar and Jones, Robert and Aapro, Matti and Zhang, Yanqiao and Wang, Jufeng and Wang, Wayne and Adeleye, Jennifer and Beelen, Andrew and Hubbard, Joleen},
title = {Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkae116}
}
EUVIMED